Cargando…
Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial
BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of L...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Pediatric Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303425/ https://www.ncbi.nlm.nih.gov/pubmed/32023397 http://dx.doi.org/10.3345/cep.2019.00381 |
_version_ | 1783548054273523712 |
---|---|
author | Serce Pehlevan, Ozge Benzer, Derya Gursoy, Tugba Karatekin, Guner Ovali, Fahri |
author_facet | Serce Pehlevan, Ozge Benzer, Derya Gursoy, Tugba Karatekin, Guner Ovali, Fahri |
author_sort | Serce Pehlevan, Ozge |
collection | PubMed |
description | BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of Lactobacillus and Bifidobacterium together with oligosaccharides and lactoferrin on the development of necrotizing enterocolitis (NEC) or sepsis in very low birth weight neonates. METHODS: Neonates with a gestational age ≤32 weeks and birth weight ≤1,500 g were enrolled. The study group received a combination of synbiotics and lactoferrin, whereas the control group received 1 mL of distilled water as placebo starting with the first feed until discharge. The outcome measures were the incidence of NEC stage ≥2 or late-onset cultureproven sepsis and NEC stage ≥2 or death. RESULTS: Mean birth weight and gestational age of the study (n=104) and the control (n=104) groups were 1,197±235 g vs. 1,151±269 g and 29±1.9 vs. 28±2.2 weeks, respectively (P>0.05). Neither the incidence of NEC stage ≥2 or death, nor the incidence of NEC stage ≥2 or late-onset culture-proven sepsis differed between the study and control groups (5.8% vs. 5.9%, P=1; 26% vs. 21.2%, P=0.51). The only significant difference was the incidence of all stages of NEC (1.9% vs. 10.6%, P=0.019). CONCLUSION: The combination of synbiotics and lactoferrin did not reduce NEC severity, sepsis, or mortality. |
format | Online Article Text |
id | pubmed-7303425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Korean Pediatric Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-73034252020-06-19 Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial Serce Pehlevan, Ozge Benzer, Derya Gursoy, Tugba Karatekin, Guner Ovali, Fahri Clin Exp Pediatr Original Article BACKGROUND: Probiotics and prebiotics have strain-specific effects on the host. Synbiotics, a mixture of probiotics and prebiotics, are proposed to have more beneficial effects on the host than either agent has alone. PURPOSE: We performed a randomized controlled trial to investigate the effect of Lactobacillus and Bifidobacterium together with oligosaccharides and lactoferrin on the development of necrotizing enterocolitis (NEC) or sepsis in very low birth weight neonates. METHODS: Neonates with a gestational age ≤32 weeks and birth weight ≤1,500 g were enrolled. The study group received a combination of synbiotics and lactoferrin, whereas the control group received 1 mL of distilled water as placebo starting with the first feed until discharge. The outcome measures were the incidence of NEC stage ≥2 or late-onset cultureproven sepsis and NEC stage ≥2 or death. RESULTS: Mean birth weight and gestational age of the study (n=104) and the control (n=104) groups were 1,197±235 g vs. 1,151±269 g and 29±1.9 vs. 28±2.2 weeks, respectively (P>0.05). Neither the incidence of NEC stage ≥2 or death, nor the incidence of NEC stage ≥2 or late-onset culture-proven sepsis differed between the study and control groups (5.8% vs. 5.9%, P=1; 26% vs. 21.2%, P=0.51). The only significant difference was the incidence of all stages of NEC (1.9% vs. 10.6%, P=0.019). CONCLUSION: The combination of synbiotics and lactoferrin did not reduce NEC severity, sepsis, or mortality. Korean Pediatric Society 2020-02-05 /pmc/articles/PMC7303425/ /pubmed/32023397 http://dx.doi.org/10.3345/cep.2019.00381 Text en Copyright © 2020 by The Korean Pediatric Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Serce Pehlevan, Ozge Benzer, Derya Gursoy, Tugba Karatekin, Guner Ovali, Fahri Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title | Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title_full | Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title_fullStr | Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title_full_unstemmed | Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title_short | Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
title_sort | synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303425/ https://www.ncbi.nlm.nih.gov/pubmed/32023397 http://dx.doi.org/10.3345/cep.2019.00381 |
work_keys_str_mv | AT sercepehlevanozge synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial AT benzerderya synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial AT gursoytugba synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial AT karatekinguner synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial AT ovalifahri synbioticsuseforpreventingsepsisandnecrotizingenterocolitisinverylowbirthweightneonatesarandomizedcontrolledtrial |